Recent Press Releases

AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan

Wednesday, 2 September 2015 AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company, Ltd. (Daiichi...

BiondVax Pharma (BVXV) Announces Planned Launch of Multimeric-001 Phase 2

BiondVax Pharma (NASDAQ: BVXV) announced the intent of the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) within the Department of...

Heat Biologics Announces Clinical Trial Combining HS-110 and PD-1 Checkpoint Inhibitor in NSCLC

Checkpoint Combination Trial to Replace Existing Trial in New Treatment Landscape; Timelines to Registration-Directed Study Remain Unchanged Conference Call and Webcast Today at 8:30 AM EDT...

NW Bio Confirms Phase III Trial of DCVax®-L for GBM Brain Cancer Is Ongoing

NW Bio Confirms Phase III Trial of DCVax®-L for GBM Brain Cancer Is Ongoing Patients In Trial Continuing To Be Treated Per Protocol, Including In Germany BETHESDA, MD, August 21, 2015 –...

Takeda and Nanotherapeutics Announce Agreement to Expand Takeda's Commercialization and Technology Access Rights in Support of Influenza and Other Vaccine Programs

ALACHUA, FL, USA I August 26, 2015 and OSAKA, Japan I August 27, 2015 I Takeda Pharmaceutical Company Limited (Takeda) and Nanotherapeutics, Inc., announced an agreement providing Takeda with...

VALNEVA Valneva Announces Two New EB66(R) Agreements

Valneva signs two new EB66® agreements with Italian firm Fatro (commercial license) and Japanese pharmaceutical company Kaketsuken (research license) The Company which has already signed seven...

New Study by TSRI and Janssen Makes Major Advance Toward More Effective, Long-Lasting Flu Vaccine

LA JOLLA, CA – August 24, 2015 – Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to...

FluGen Closes $12 Million Series A Financing

Industry Veterans Dan Stinchcomb and C. Boyd Clarke Join FluGen's Board of Directors August 25, 2015 09:00 AM Eastern Daylight Time MADISON, Wis--(BUSINESS WIRE)--FluGen Inc., a biotechnology...

Pfizer's (PFE) TRUMENBA Shows Positive Results in Two Phase 3 Studies

Pfizer Inc. (NYSE: PFE) announced today positive topline results of two Phase 3 studies of TRUMENBA® (Meningococcal Group B Vaccine). One study included approximately 3,600 healthy individuals 10...

Emergent BioSolutions Receives $44 Million CDC Contract to Further Advance Vaccinia Immune Globulin Intravenous Program

GAITHERSBURG, Md., Aug 13, 2015 (GLOBE NEWSWIRE via COMTEX) -- Emergent BioSolutions Inc. EBS, -0.24% today announced that the Centers for Disease Control and Prevention (CDC) has exercised options...

Madison Vaccines Announces Patient Dosing Underway in Clinical Trial Pairing Its Lead Prostate Cancer Vaccine, MVI-816, with PD1 Inhibitor Pembrolizumab

--Trial Will Test Potential Synergy of the Two Immunomodulatory Approaches on Men with Metastatic, Castrate-Resistant Prostate Cancer-- --Trial Underway at the University of Wisconsin-Madison--...

NIH-developed Epstein-Barr virus vaccine elicits potent neutralizing antibodies in animals

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators have developed an experimental,...

Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine

Awarded $2.7 million in additional funding PRINCETON, N.J., Aug. 19, 2015-- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address...

Inovio Pharmaceuticals DNA Vaccine Protects 100% Against Deadly MERS Virus in Non-Human Primates

Promising data on preventive vaccine appears in the peer-reviewed journal Science Translational Medicine PLYMOUTH MEETING, Pa. – August 19, 2015 – Inovio Pharmaceuticals (NASDAQ: INO)...

Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN(r) in Respiratory Syncitial Virus (RSV)

COPENHAGEN, Denmark, Aug. 18, 2015 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation of a Phase 1 clinical study of its MVA-BN® RSV vaccine candidate...

Development of new anthrax vaccine underway with HHS support

Project is the latest in the quest to protect health quickly in a bioterrorism attack A new anthrax vaccine that could be easier and faster to produce than the existing licensed product will undergo...

Vaccine hesitancy: A growing challenge for immunization programmes

18 AUGUST 2015 | GENEVA - People who delay or refuse vaccines for themselves or their children are presenting a growing challenge for countries seeking to close the immunization gap. Globally, 1 in 5...

CMC Biologics Enters into Agreement with the PATH Malaria Vaccine Initiative for Accelerated Development and Manufacturing of Monoclonal Antibodies

SEATTLE and BERKELEY, Calif., Aug. 12, 2015 /PRNewswire/ -- CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it...

Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults

- First respiratory syncytial virus (RSV) vaccine to demonstrate efficacy in any population - Statistically significant vaccine efficacy in prevention of symptomatic RSV disease in older adults -...

Medimmune enters into strategic cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals

Medimmune enters into strategic cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals Monday, 10 August 2015 Agreement includes clinical-stage INO-3112 HPV cancer vaccine and...